Institution
University of Antwerp
Education•Antwerp, Belgium•
About: University of Antwerp is a education organization based out in Antwerp, Belgium. It is known for research contribution in the topics: Population & Context (language use). The organization has 16682 authors who have published 48837 publications receiving 1689748 citations. The organization is also known as: Universiteit Antwerpen & UAntwerp.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, the authors identify determinants of corporate environmental disclosure using multi-theoretical lenses that rely on economic incentives, public pressures and institutional theory, focusing on large firms from a continental Europe country, Germany, with a distinct legal and regulatory context and where environmental concerns are especially acute.
Abstract: Investors and stakeholders in continental Europe are becoming increasingly concerned about corporate environmental policies. As a result, many firms are voluntarily increasing the extent of their environmental disclosure in their annual report. While mostly unregulated, corporate environmental disclosure does have potential economic significance considering the scarcity of alternative information sources. The purpose of this study is to identify determinants of corporate environmental disclosure using multi-theoretical lenses that rely on economic incentives, public pressures and institutional theory. The study focuses on large firms from a continental Europe country, Germany, with a distinct legal and regulatory context and where environmental concerns are especially acute. Results show that Risk, Ownership, Fixed Assets Age, Firm Size as well as routine determine the level of environmental disclosure by German firms in a given year. Moreover, consistent with institutional theory, results sugge...
887 citations
••
Monash University1, Kaiser Permanente2, Pennington Biomedical Research Center3, Copenhagen University Hospital4, Ewha Womans University5, Norwegian Institute of Public Health6, Michigan State University7, Dankook University8, University of Antwerp9, Katholieke Universiteit Leuven10, University of California, Irvine11
TL;DR: More than 1 million pregnant women had gestational weight gain greater than or less than guideline recommendations, compared with weight gain within recommended levels, was associated with higher risk of adverse maternal and infant outcomes.
Abstract: Importance Body mass index (BMI) and gestational weight gain are increasing globally. In 2009, the Institute of Medicine (IOM) provided specific recommendations regarding the ideal gestational weight gain. However, the association between gestational weight gain consistent with theIOM guidelines and pregnancy outcomes is unclear. Objective To perform a systematic review, meta-analysis, and metaregression to evaluate associations between gestational weight gain above or below the IOM guidelines (gain of 12.5-18 kg for underweight women [BMI Data Sources and Study Selection Search of EMBASE, Evidence-Based Medicine Reviews, MEDLINE, and MEDLINE In-Process between January 1, 1999, and February 7, 2017, for observational studies stratified by prepregnancy BMI category and total gestational weight gain. Data Extraction and Synthesis Data were extracted by 2 independent reviewers. Odds ratios (ORs) and absolute risk differences (ARDs) per live birth were calculated using a random-effects model based on a subset of studies with available data. Main Outcomes and Measures Primary outcomes were small for gestational age (SGA), preterm birth, and large for gestational age (LGA). Secondary outcomes were macrosomia, cesarean delivery, and gestational diabetes mellitus. Results Of 5354 identified studies, 23 (n = 1 309 136 women) met inclusion criteria. Gestational weight gain was below or above guidelines in 23% and 47% of pregnancies, respectively. Gestational weight gain below the recommendations was associated with higher risk of SGA (OR, 1.53 [95% CI, 1.44-1.64]; ARD, 5% [95% CI, 4%-6%]) and preterm birth (OR, 1.70 [1.32-2.20]; ARD, 5% [3%-8%]) and lower risk of LGA (OR, 0.59 [0.55-0.64]; ARD, −2% [−10% to −6%]) and macrosomia (OR, 0.60 [0.52-0.68]; ARD, −2% [−3% to −1%]); cesarean delivery showed no significant difference (OR, 0.98 [0.96-1.02]; ARD, 0% [−2% to 1%]). Gestational weight gain above the recommendations was associated with lower risk of SGA (OR, 0.66 [0.63-0.69]; ARD, −3%; [−4% to −2%]) and preterm birth (OR, 0.77 [0.69-0.86]; ARD, −2% [−2% to −1%]) and higher risk of LGA (OR, 1.85 [1.76-1.95]; ARD, 4% [2%-5%]), macrosomia (OR, 1.95 [1.79-2.11]; ARD, 6% [4%-9%]), and cesarean delivery (OR, 1.30 [1.25-1.35]; ARD, 4% [3%-6%]). Gestational diabetes mellitus could not be evaluated because of the nature of available data. Conclusions and Relevance In this systematic review and meta-analysis of more than 1 million pregnant women, 47% had gestational weight gain greater than IOM recommendations and 23% had gestational weight gain less than IOM recommendations. Gestational weight gain greater than or less than guideline recommendations, compared with weight gain within recommended levels, was associated with higher risk of adverse maternal and infant outcomes.
881 citations
••
University of British Columbia1, University of Zurich2, Northwestern University3, Washington University in St. Louis4, Uppsala University5, University of Sydney6, Medical University of Vienna7, Indiana University8, University of New South Wales9, Aarhus University10, University of Sheffield11, VU University Amsterdam12, University College London13, University of Antwerp14, Walton Centre15, Mayo Clinic16, University of Pennsylvania17, University of Manchester18
TL;DR: A system of nosology was introduced that grouped the FTLD subtypes into broad categories, based on the molecular defect that is most characteristic, according to current evidence, and provided a concise and consistent terminology that has now been widely adopted in the literature.
Abstract: Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration : an update
878 citations
••
876 citations
••
TL;DR: The role of DPP IV/CD26 within the immune system is a combination of its exopeptidase activity and its interactions with different molecules to serve as a co-stimulatory molecule to influence T cell activity and to modulate chemotaxis.
Abstract: Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the prolyloligopeptidase family. It selectively removes the N-terminal dipeptide from peptides with proline or alanine in the second position. Apart from its catalytic activity, it interacts with several proteins, for instance, adenosine deaminase, the HIV gp120 protein, fibronectin, collagen, the chemokine receptor CXCR4, and the tyrosine phosphatase CD45. DPP IV is expressed on a specific set of T lymphocytes, where it is up-regulated after activation. It is also expressed in a variety of tissues, primarily on endothelial and epithelial cells. A soluble form is present in plasma and other body fluids. DPP IV has been proposed as a diagnostic or prognostic marker for various tumors, hematological malignancies, immunological, inflammatory, psychoneuroendocrine disorders, and viral infections. DPP IV truncates many bioactive peptides of medical importance. It plays a role in glucose homeostasis through proteolytic inactivation of...
865 citations
Authors
Showing all 16957 results
Name | H-index | Papers | Citations |
---|---|---|---|
Cornelia M. van Duijn | 183 | 1030 | 146009 |
John Hardy | 177 | 1178 | 171694 |
Mark Gerstein | 168 | 751 | 149578 |
Hannes Jung | 159 | 2069 | 125069 |
Rui Zhang | 151 | 2625 | 107917 |
Dirk Inzé | 149 | 647 | 74468 |
Walter Paulus | 149 | 809 | 86252 |
Robin Erbacher | 138 | 1721 | 100252 |
Rupert Leitner | 136 | 1201 | 90597 |
Alison Goate | 136 | 721 | 85846 |
Andrea Giammanco | 135 | 1362 | 98093 |
Maria Spiropulu | 135 | 1455 | 96674 |
Peter Robmann | 135 | 1438 | 97569 |
Michael Tytgat | 134 | 1449 | 94133 |
Matthew Herndon | 133 | 1732 | 97466 |